Nektarios Barabutis1, Vikramjit Khangoora2, Paul E Marik2, John D Catravas3. 1. Frank Reidy Research Center for Bioelectrics, College of Health Sciences, Old Dominion University, Norfolk, VA. 2. Division of Pulmonary and Critical Care Medicine, Eastern Virginia Medical School, Norfolk, VA. 3. School of Medical Diagnostic and Translational Sciences, College of Health Sciences, Old Dominion University, Norfolk, VA; Departments of Medicine and Physiological Sciences, Eastern Virginia Medical School, Norfolk, VA. Electronic address: jcatrava@odu.edu.
Abstract
BACKGROUND: Sepsis refers to the dysregulated host immune response elicited by microbial infections resulting in life-threatening organ dysfunction. Sepsis represents a medical challenge, since it is associated with a rate of death as high as 60%. Septic shock is strongly associated with vascular dysfunction and elevated pulmonary capillary permeability. We recently reported that the combination of hydrocortisone (HC), ascorbic acid (vitC), and thiamine dramatically improves outcomes and reduces mortality in patients with sepsis. In the present study, we provide experimental evidence in support of the hypothesis that the combination of HC and vitC enhances endothelial barrier function. METHODS: Human lung microvascular endothelial cells were exposed to lipopolysaccharide (LPS) in the absence or presence of HC and vitC. RESULTS: LPS alone induced profound hyperpermeability, as reflected in decreased values of transendothelial electrical resistance. vitC alone did not exhibit barrier enhancement properties nor did it affect the LPS-induced hyperpermeability. Similarly, HC alone exhibited only a minor barrier-enhancing and protective effect. Conversely, the combination of HC and vitC, either as before or after treatment, dramatically reversed the LPS-induced barrier dysfunction. The barrier-protective effects of HC and vitC were associated with reversal of LPS-induced p53 and phosphorylated cofilin downregulation and LPS-induced RhoA activation and myosin light chain phosphorylation. CONCLUSIONS: These data provide a novel mechanism of endothelial barrier protection and suggest one possible pathway that may contribute to the therapeutic effects of HC and vitC in patients with sepsis.
BACKGROUND:Sepsis refers to the dysregulated host immune response elicited by microbial infections resulting in life-threatening organ dysfunction. Sepsis represents a medical challenge, since it is associated with a rate of death as high as 60%. Septic shock is strongly associated with vascular dysfunction and elevated pulmonary capillary permeability. We recently reported that the combination of hydrocortisone (HC), ascorbic acid (vitC), and thiamine dramatically improves outcomes and reduces mortality in patients with sepsis. In the present study, we provide experimental evidence in support of the hypothesis that the combination of HC and vitC enhances endothelial barrier function. METHODS:Human lung microvascular endothelial cells were exposed to lipopolysaccharide (LPS) in the absence or presence of HC and vitC. RESULTS:LPS alone induced profound hyperpermeability, as reflected in decreased values of transendothelial electrical resistance. vitC alone did not exhibit barrier enhancement properties nor did it affect the LPS-induced hyperpermeability. Similarly, HC alone exhibited only a minor barrier-enhancing and protective effect. Conversely, the combination of HC and vitC, either as before or after treatment, dramatically reversed the LPS-induced barrier dysfunction. The barrier-protective effects of HC and vitC were associated with reversal of LPS-induced p53 and phosphorylated cofilin downregulation and LPS-induced RhoA activation and myosin light chain phosphorylation. CONCLUSIONS: These data provide a novel mechanism of endothelial barrier protection and suggest one possible pathway that may contribute to the therapeutic effects of HC and vitC in patients with sepsis.
Authors: Martijn D de Kruif; Lucienne C Lemaire; Ida A Giebelen; Marieke A D van Zoelen; Jennie M Pater; Petra S van den Pangaart; Angelique P Groot; Alex F de Vos; Peter J Elliott; Joost C M Meijers; Marcel Levi; Tom van der Poll Journal: J Immunol Date: 2007-02-01 Impact factor: 5.422
Authors: Sameer S Kadri; Chanu Rhee; Jeffrey R Strich; Megan K Morales; Samuel Hohmann; Jonathan Menchaca; Anthony F Suffredini; Robert L Danner; Michael Klompas Journal: Chest Date: 2016-07-22 Impact factor: 9.410
Authors: Simon T Schäfer; Sophia Gessner; André Scherag; Katharina Rump; Ulrich H Frey; Winfried Siffert; Astrid M Westendorf; Jörg Steinmann; Jürgen Peters; Michael Adamzik Journal: PLoS One Date: 2014-08-18 Impact factor: 3.240
Authors: Mohammad A Uddin; Mohammad S Akhter; Agnieszka Siejka; John D Catravas; Nektarios Barabutis Journal: Immunobiology Date: 2019-04-18 Impact factor: 3.144
Authors: Ari Moskowitz; David T Huang; Peter C Hou; Jonathan Gong; Pratik B Doshi; Anne V Grossestreuer; Lars W Andersen; Long Ngo; Robert L Sherwin; Katherine M Berg; Maureen Chase; Michael N Cocchi; Jessica B McCannon; Mark Hershey; Ayelet Hilewitz; Maksim Korotun; Lance B Becker; Ronny M Otero; Junior Uduman; Ayan Sen; Michael W Donnino Journal: JAMA Date: 2020-08-18 Impact factor: 56.272